var data={"title":"Febuxostat: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Febuxostat: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/376230?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=febuxostat-patient-drug-information\" class=\"drug drug_patient\">see &quot;Febuxostat: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50786724\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Febuxostat Safety Alert</span>\n      <span class=\"collapsible-date\">November 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA is providing notification that preliminary results from a safety clinical trial showed an increased risk of heart-related death with Takeda Pharmaceuticals' febuxostat (Uloric) compared with allopurinol. The FDA required the manufacturer to conduct this safety study when the drug was approved in 2009. Once the final results are received, the FDA will conduct a comprehensive review and will provide an update with any new information. Health care providers should consider this safety information when deciding whether to prescribe or continue patients on febuxostat.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm585281.htm&amp;token=KotXH/fcXZ3m2BwggP3LlxGfHHW/Hc1SUmBwJPOrBTLtWeGzmdzp8ZygnDbRnuVRIMgFoppUqtgYZLUFJ2dV9LykrwMplIg928ox1I99yBVvMIkw+4oCL+ufgqoqrJbQ6PsfPa8KVHCl0c0t4ONm6g==&amp;TOPIC_ID=9079\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm585281.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7254933\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Uloric</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11508520\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Uloric</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258706\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antigout Agent;</li>\n      <li>\n        Xanthine Oxidase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258764\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>It is recommended to take an NSAID or colchicine with initiation of therapy and may continue for up to 6 months to help prevent gout flares. If a gout flare occurs, febuxostat does not need to be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperuricemia: </b>Oral: Initial: 40 mg once daily; may increase to 80 mg once daily in patients who do not achieve a serum uric acid level &lt;6 mg/dL after 2 weeks. The dose may be increased further to 120 mg once daily if clinically indicated (ACR guidelines [Khanna 2012]; EULAR [Richette 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258765\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258766\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (CrCl 30 to 89 mL/minute): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (CrCl &lt;30 mL/minute): Maximum dose: 40 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). A small pharmacokinetic study involving an extremely limited number of Japanese hemodialysis patients (n=3) receiving 10 to 20 mg/day showed that pharmacokinetics were not altered (Hira 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258767\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258774\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Uloric: 40 mg, 80 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258704\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258769\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with or without meals or antacids.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258707\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperuricemia:</b> Chronic management of hyperuricemia in patients with gout.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not recommended for treatment of asymptomatic hyperuricemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258744\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Liver function abnormalities (5% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal electroencephalogram, abnormal gait, aggressive behavior, agitation, agranulocytosis, alopecia, anaphylaxis, anemia, angina pectoris, angioedema, anorexia, anxiety, arthralgia, atrial fibrillation, atrial flutter, blurred vision, bruise, cardiac failure, cerebral infarction, cerebrovascular accident, cerebrovascular accident, cholecystitis, cholelithiasis, constipation, deafness, decreased hematocrit, decreased libido, decreased serum bicarbonate, decreased urine output, dehydration, depression, dermatitis, diabetes mellitus, DRESS syndrome, dysgeusia, dyspepsia, dyspnea, ECG abnormality, eczema, edema, eosinophilia, epistaxis, erectile dysfunction, erythema multiforme, flu-like symptoms, flushing, gastritis, gastroesophageal reflux disease, gingival pain, Guillain-Barr&eacute; syndrome, gynecomastia, hair discoloration, heart murmur, hematemesis, hematochezia, hematuria, hemiparesis, hepatic failure, hepatitis, hepatomegaly, herpes zoster, hirsutism, hot flash, hyperacidity, hypercholesterolemia, hyperglycemia, hyperhidrosis, hyperkalemia, hyperlipidemia, hypernatremia, hypersensitivity reaction, hypertension, hypertriglyceridemia, hypokalemia, hypotension, immune thrombocytopenia, increased amylase, increased blood urea nitrogen, increased creatine phosphokinase, increased lactate dehydrogenase, increased MCV, increased serum alkaline phosphatase, increased serum creatinine, increased thyroid stimulating hormone level, increased urine output, interstitial nephritis, jaundice, joint swelling, lethargy, leukocytosis, leukopenia, liver steatosis, lymphocytopenia, migraine, muscle spasm, muscle twitching, myalgia, myocardial infarction, nephrolithiasis, neutropenia, oral mucosa ulcer, pain, palpitations, pancreatitis, pancytopenia, panic attack, paresthesia, peptic ulcer, personality changes, petechia, pharyngeal edema, pollakiuria, prolonged partial thromboplastin time, prolonged prothrombin time, prostate specific antigen increase, proteinuria, psychotic symptoms, renal failure, respiratory tract infection, rhabdomyolysis, sinus bradycardia, skin discoloration, skin photosensitivity, splenomegaly, Stevens-Johnson syndrome, tachycardia, thrombocytopenia, tinnitus, toxic epidermal necrolysis, transient ischemic attacks, tremor, urinary incontinence, urinary tract infection, urticaria (including dermographism), vertigo, vomiting, weakness, weight gain, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258712\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concurrent use with azathioprine or mercaptopurine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to febuxostat or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258713\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic failure: Postmarketing cases of hepatic failure (both fatal and nonfatal) have been reported (causal relationship has not been established). In controlled studies, significant hepatic transaminase elevations (&gt;3 x ULN) have occurred (causal relationship not established). Liver function tests should be evaluated at baseline and periodically thereafter; evaluate liver function tests promptly in patients experiencing signs and symptoms of hepatic injury (eg, fatigue, anorexia, right upper quadrant pain, dark urine, jaundice). Interrupt therapy in patients who develop abnormal liver function tests (eg, ALT &gt;3 x ULN); permanently discontinue use if no other explanation for the abnormalities is elucidated and in patients who develop ALT &gt;3 x ULT <b>and</b> serum total bilirubin &gt;2 x ULN. All other patients may be cautiously restarted on febuxostat.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity and serious skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS) have been reported, particularly in patients with prior skin reactions to allopurinol; use with caution if a patient has a history of hypersensitivity reaction to allopurinol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: MI, stroke and cardiovascular deaths were reported at a slightly increased rate versus allopurinol in controlled studies (a causal relationship has not been established). Patients should be monitored for signs and symptoms of MI or stroke.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment (Child-Pugh class C); has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary hyperuricemia: Use in secondary hyperuricemia has not been studied; avoid use in patients at increased risk of urate formation (eg, malignancy and its treatment; Lesch-Nyhan syndrome).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage forms specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Contains lactose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Administer concurrently with an NSAID or colchicine (up to 6 months) to prevent gout flare, which may occur upon initiation of therapy. Do not use to treat asymptomatic or secondary hyperuricemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299314\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7273306\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9079&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Febuxostat may increase the serum concentration of AzaTHIOprine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Febuxostat may increase the serum concentration of Didanosine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: Febuxostat may increase the serum concentration of Mercaptopurine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: Febuxostat may enhance the adverse/toxic effect of Pegloticase. Specifically, Febuxostat may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Febuxostat may increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258709\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16354745\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if febuxostat is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258771\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests at baseline and then periodically, serum uric acid levels (as early as 2 weeks after initiation); signs/symptoms of MI or stroke, signs/symptoms of hypersensitivity or severe skin reactions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258753\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Uric acid, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Normal values:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Males: 3.4 to 7 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females: 2.4 to 6 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Goal during therapy: &lt;6 mg/dL; &lt;5 mg/dL in patients with severe gout (eg, tophi, frequent attacks, chronic arthropathy) (ACR [Khanna 2012]; EULAR [Richette 2017]). Levels &lt;3 mg/dL are not recommended long-term (EULAR [Richette 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Serum uric acid values &gt;7 mg/dL do not necessarily represent clinical gout; current clinical practice guidelines do not address pharmacologic management of asymptomatic hyperuricemia (ACR guidelines [Khanna 2012]; EULAR [Richette 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258751\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selectively inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine to uric acid thereby decreasing uric acid. At therapeutic concentration does not inhibit other enzymes involved in purine and pyrimidine synthesis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7258754\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: &ge;49%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: ~50 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~99%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensive conjugation via uridine diphosphate glucuronosyltransferases (UGTs) 1A1, 1A3, 1A9, and 2B7 and oxidation via cytochrome P450 (CYP) 1A2, 2C8, and 2C9 as well as non-P450 enzymes. Oxidation leads to formation of active metabolites (67M-1, 67M-2, 67M-4)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~5 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1 to 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~49% mostly as metabolites, 3% as unchanged drug); feces (~45% mostly as metabolites, 12% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7679963\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Uloric Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $384.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $384.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390221\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adenuric (AT, BE, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HR, HU, IE, IT, LB, LT, LU, LV, MT, NL, NZ, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>Adenurik (UA);</li>\n      <li>Agout (SA);</li>\n      <li>Atenurix (PH);</li>\n      <li>Fabuzest (IN);</li>\n      <li>Febsan (PH);</li>\n      <li>Febuday (LK);</li>\n      <li>Feburic (HK, IL, JP, KR, MY, SG, TH, TW, VN);</li>\n      <li>Febus (BD);</li>\n      <li>Febustad (VN);</li>\n      <li>Febux (BD);</li>\n      <li>Febuxtat (AR);</li>\n      <li>Fexorin (KR);</li>\n      <li>Fexurix (CL);</li>\n      <li>Furic (PH);</li>\n      <li>Goustat (BD);</li>\n      <li>Goutex (CO);</li>\n      <li>Goutil (BD);</li>\n      <li>Rui Yang (CN);</li>\n      <li>Turazive (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Urinorm (PH);</li>\n      <li>Urostat (BD);</li>\n      <li>Zurig (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bruce SP. Febuxostat: A Selective Xanthine Oxidase Inhibitor for the Treatment of Hyperuricemia and Gout. <i>Ann Pharmacother</i>. 2006;40(12):2187-2194.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hira D, Chisaki Y, Noda S, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. <i>Pharmacology</i>. 2015;96(1-2):90-98. doi: 10.1159/000434633.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/26183164/pubmed\" target=\"_blank\" id=\"26183164\">26183164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khanna D, Fitzgerald JD, Khanna PP, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(10):1431-1446.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/23024028/pubmed\" target=\"_blank\" id=\"23024028\">23024028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/27457514/pubmed\" target=\"_blank\" id=\"27457514\">27457514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Ann Rheum Dis</i>. 2014;73(2):328-335.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/23868909/pubmed\" target=\"_blank\" id=\"23868909\">23868909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang W, Doherty M, Bardin T, et al; <span style=\"text-decoration: underline\">EULAR Standing Committee for International Clinical Studies Including Therapeutics</span>. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Ann Rheum Dis</i>. 2006;65(10):1312-1324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/16707532/pubmed\" target=\"_blank\" id=\"16707532\">16707532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uloric (febuxostat) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uloric (febuxostat) [product monograph]. Oakville, Ontario, Canada: Takeda Canada Inc; February 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9079 Version 117.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50786724\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7254933\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11508520\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7258706\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7258764\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7258765\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7258766\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7258767\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7258774\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F7258704\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7258769\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7258707\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7258744\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7258712\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7258713\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299314\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7273306\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7258709\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16354745\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7258771\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F7258753\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7258751\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7258754\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F7679963\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390221\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9079|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=febuxostat-patient-drug-information\" class=\"drug drug_patient\">Febuxostat: Patient drug information</a></li></ul></div></div>","javascript":null}